
    
      This is a Phase IIb, randomized, double-blind, placebo-controlled, multicenter,
      4-parallel-group, dose ranging, superiority study evaluating the dose response, efficacy and
      safety of weekly and every other week subcutaneously injected GSK716155 (albiglutide) in
      subjects with type 2 diabetes mellitus.
    
  